Risk and medical decision making
著者
書誌事項
Risk and medical decision making
(Studies in risk and uncertainty)
Kluwer Academic Publishers, c2002
大学図書館所蔵 全11件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references (p. [132]-134) and index
内容説明・目次
内容説明
For people interested in risk management, medical activity represents a stimulating field of study and thought. On the one hand, progress in medical knowledge and technology tends to reduce the risks to survival that individuals would face in the absence of appropriate diagnostic or therapeutic instruments. On the other hand, new medical technologies simultaneously create their own specific risks, sometimes simply because their effects are less well-known than those of established ones. In a sense any medical progress simultaneously generates new risks while destroying old ones. Moreover, unlike many financial risks that can be either divided or transferred to others (e.g. through diversification, insurance or social security) the personal aspects of medical risks are by essence indivisible and non-transferable. As a result, they are in a sense more threatening than financial risks for risk averse patients. These two facts explain and justify the growing interest in risk economics for the fields of medical decision making and health economics.
In Risk and Medical Decision Making, part 1 is developed inside the expected utility (E-U) model and analyses how comorbidity risks affect the well-known "test-treatment" thresholds. Part 2 is devoted to a specific non E-U model with the same purpose: how would one define a threshold in this context and how would one value a diagnostic test? In each of these two parts both diagnostic and therapeutic risks are considered.
目次
Preface. 1. Introduction.
Part 1: Developments inside the E-U model. 2. The case of diagnostic risks in a single risk environment. 3. The introduction of 'comorbidity risks' and the treatment threshold. The notion of prudence. 4. Treatment decisions under therapeutic risks. 5. The value of diagnostic tests (under risk neutrality). 6. Risk aversion and diagnostic tests. 7. Comorbidity risks and the value of a test: a short overview.
Part 2: M.D.M. and new models of choice under risk. 8. Treatment thresholds and the dual theory of choice under risk. 9. Diagnostic tests and the dual theory.
Conclusions. References. Index.
「Nielsen BookData」 より